Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference
September 23, 2019 08:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular...
Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics
August 27, 2019 08:00 ET
|
Celsion CORP
Data show overall survival improvement of 22.5 months with ThermoDox® plus RFA of 45 minutes or longer Data provides additional corroboration of ThermoDox’s potential for superior efficacy when...
Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology
August 13, 2019 08:00 ET
|
Celsion CORP
NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox® Improves Overall Survival with Significance in Patients with...
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
August 05, 2019 09:00 ET
|
Celsion CORP
Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
June 20, 2019 08:30 ET
|
Celsion CORP
An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range...
Celsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update
May 15, 2019 08:00 ET
|
Celsion CORP
Company to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J, May 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug...
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
April 12, 2019 08:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., April 12, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Celsion Corporation Reports 2018 Financial Results
March 29, 2019 08:00 ET
|
Celsion CORP
Celsion Enters 2019 with a Strong Balance Sheet, Clean Capitalization Structure and an Advancing Clinical Pipeline Company to Hold Conference Call on Friday, March 29, 2019 at 11:00 a.m. EDT ...
Celsion Corporation to Hold Year-End 2018 Financial Results Conference Call on Friday, March 29, 2019
March 22, 2019 08:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J, March 22, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended...
Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 21, 2019 16:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on February 19, 2019, the Compensation Committee...